Oragenics (OGEN) Competitors $4.36 -0.27 (-5.83%) Closing price 04:00 PM EasternExtended Trading$4.31 -0.05 (-1.15%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. ALLO, GLUE, CADL, ATXS, GOSS, SLDB, AVIR, CRVS, OLMA, and PVLAShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Allogene Therapeutics (ALLO), Monte Rosa Therapeutics (GLUE), Candel Therapeutics (CADL), Astria Therapeutics (ATXS), Gossamer Bio (GOSS), Solid Biosciences (SLDB), Atea Pharmaceuticals (AVIR), Corvus Pharmaceuticals (CRVS), Olema Pharmaceuticals (OLMA), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Allogene Therapeutics Monte Rosa Therapeutics Candel Therapeutics Astria Therapeutics Gossamer Bio Solid Biosciences Atea Pharmaceuticals Corvus Pharmaceuticals Olema Pharmaceuticals Palvella Therapeutics Oragenics (NYSE:OGEN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Which has higher valuation and earnings, OGEN or ALLO? Oragenics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K77.94-$20.66M-$33.63-0.13Allogene Therapeutics$22K13,322.71-$327.27M-$1.23-1.09 Does the MarketBeat Community prefer OGEN or ALLO? Allogene Therapeutics received 290 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 66.21% of users gave Allogene Therapeutics an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes55100.00% Allogene TherapeuticsOutperform Votes29066.21% Underperform Votes14833.79% Do insiders & institutionals believe in OGEN or ALLO? 18.7% of Oragenics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.9% of Oragenics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is OGEN or ALLO more profitable? Allogene Therapeutics' return on equity of -52.13% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% Allogene Therapeutics N/A -52.13%-41.29% Does the media prefer OGEN or ALLO? In the previous week, Allogene Therapeutics had 1 more articles in the media than Oragenics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Oragenics. Allogene Therapeutics' average media sentiment score of 1.03 beat Oragenics' score of 0.48 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oragenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend OGEN or ALLO? Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 530.18%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more risk and volatility, OGEN or ALLO? Oragenics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. SummaryAllogene Therapeutics beats Oragenics on 13 of the 17 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.12M$6.88B$5.58B$19.65BDividend YieldN/A2.53%5.28%3.82%P/E Ratio-0.628.5527.1935.03Price / Sales77.94262.61408.7842.85Price / CashN/A65.8538.3217.51Price / Book7.156.536.974.78Net Income-$20.66M$143.48M$3.23B$1.02B7 Day Performance1.87%0.20%-0.88%-0.35%1 Month Performance-25.85%10.93%7.81%1.04%1 Year Performance-91.40%2.46%31.53%9.19% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.4574 of 5 stars$4.36-5.8%N/A-91.0%$3.12M$40K-0.625Short Interest ↓Gap DownALLOAllogene Therapeutics3.8535 of 5 stars$1.34-1.1%$8.44+532.5%-45.5%$292.01M$22K-0.86310Positive NewsGap DownGLUEMonte Rosa Therapeutics2.2939 of 5 stars$4.74+2.2%$15.50+226.9%+18.3%$291.62M$159.49M-2.5990CADLCandel Therapeutics2.9413 of 5 stars$5.82+1.1%$21.00+261.1%-29.3%$291.40M$120K-3.3660Positive NewsATXSAstria Therapeutics2.357 of 5 stars$5.06+1.9%$30.00+493.4%-39.7%$288.66MN/A-2.4530News CoverageAnalyst ForecastAnalyst RevisionGOSSGossamer Bio3.8052 of 5 stars$1.25+2.0%$7.75+522.5%+144.0%$282.99M$124.59M-3.89180Positive NewsAnalyst RevisionSLDBSolid Biosciences3.8823 of 5 stars$3.62+3.4%$14.90+311.6%-42.2%$280.60M$8.09M-1.19100Positive NewsAnalyst RevisionGap DownAVIRAtea Pharmaceuticals3.359 of 5 stars$3.24+4.5%$6.00+85.2%-15.1%$278.13MN/A-1.5770Positive NewsCRVSCorvus Pharmaceuticals2.8439 of 5 stars$4.08-1.0%$15.00+267.6%+104.8%$278.13MN/A-4.3930Positive NewsAnalyst RevisionOLMAOlema Pharmaceuticals2.1165 of 5 stars$3.98-1.8%$24.50+516.0%-68.5%$273.75MN/A-1.8370Gap DownPVLAPalvella Therapeutics3.9976 of 5 stars$24.44-2.8%$46.29+89.4%N/A$270.21M$42.81M-2.02N/APositive NewsAnalyst Revision Related Companies and Tools Related Companies Allogene Therapeutics Competitors Monte Rosa Therapeutics Competitors Candel Therapeutics Competitors Astria Therapeutics Competitors Gossamer Bio Competitors Solid Biosciences Competitors Atea Pharmaceuticals Competitors Corvus Pharmaceuticals Competitors Olema Pharmaceuticals Competitors Palvella Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGEN Stock Free OGEN Stock Alerts